Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma.
This review presents the most important hormonal, cytotoxic and pharmacokinetic properties of estramustine phosphate. Furthermore the results of randomized Phase III trials are described in patients with hormone refractory prostatic cancer with and without previous irradiation. Several randomized studies are reported with Estracyt also in the primary treatment of this disease.
Könyves
I
I
Pharmacia-LEO Therapeutics AB, Helsingborg, Sweden.
D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
D009588:Nitrogen Mustard Compounds; D004961:Estramustine